Z80.3 Insurance Policy Changes

ICD-10 Z80.3 is officially defined as "Family history of malignant neoplasm of breast." code Z80.3 is referenced in 10 tracked payer policy changes from Capital Blue Cross, Blue Cross & Blue Shield of Mississippi, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z80.3 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Capital Blue Cross · Effective Mar 1, 2026High impact
AB2026-01-001 Updates and new information
Effective March 1, 2026, a number of codes newly require preauthorization for Commercial and Medicare Advantage members, including 20985, 22100 and 27860, and HCPCS code H0032 will be denied because the service is not provided directly to members. Codes C1605, C1721 and others no longer require preauthorization effective February 1, 2026, Evolent updated its CT, MRI, PET and cardiac imaging policies effective March 1, 2026, and TurningPoint accepts listed substitute codes for a limited group of musculoskeletal surgical procedures effective February 1, 2026. Effective for claims processed on or after March 1, 2026, facility claims with modifiers 59, XE, XP, XS and XU that do not meet the CMS criteria to bypass an NCCI procedure-to-procedure edit will be rejected, and physical medicine code 97140 is not separately reimbursed when billed with chiropractic manipulative treatment in the same anatomical region.
Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Risk-Reducing Mastectomy
Risk-reducing mastectomy may be considered medically necessary for individuals at high risk of breast cancer, including those with lobular carcinoma in situ, a known BRCA1 or BRCA2 variant, another high-risk gene variant such as TP53, PTEN, CDH1, STK11 or PALB2, or chest radiotherapy before 30 years of age. It is considered investigational for all other indications, including contralateral risk-reducing mastectomy in individuals with breast cancer who do not meet high-risk criteria. On 10/01/2026 the code reference was updated to add ICD-10 diagnosis codes QA1.790, QA1.791 and QA1.792.
Excellus BlueCross BlueShield · Effective Apr 16, 2026Medium impact
Germline Genetic Testing for Hereditary Cancers 2.02.60
Excellus BlueCross BlueShield policy 2.02.60 considers germline genetic testing for hereditary cancer medically appropriate in listed circumstances, including when a blood relative has a known pathogenic or likely pathogenic variant, when a pathogenic or likely pathogenic variant is found on tumor genomic testing, when results aid systemic therapy or surgical decisions, and when individuals meet specific criteria for breast, ovarian, pancreatic, prostate, colorectal, Cowden syndrome, Li-Fraumeni syndrome, hereditary diffuse gastric cancer or familial medullary thyroid carcinoma. Multigene panel testing is considered medically appropriate when an individual meets Policy Statement I, except Policy Statements I.A, I.D and I.G.9. The current effective date is April 16, 2026, and the annual update kept the policy intent unchanged.
Florida Blue · Effective Jan 1, 2026Medium impact
2026 Breast Cancer Screening Coverage Updates
Effective January 1, 2026, Florida Blue and Truli for Health will expand preventive breast cancer screening coverage for women 40+ to include additional imaging (MRI, ultrasound, additional mammography) and pathology evaluation with $0 member cost share when needed to complete screening or investigate initial mammogram findings. Prior authorization will still be required for breast MRI.
Aetna · Identified Oct 5, 2026Medium impact
Mammography (CPB 0584, reviewed 2026-09-10)
Annual screening mammography is medically necessary for women aged 40 and older as a preventive service, and for women under 40 who are judged to be at high risk, such as BRCA1 or BRCA2 mutation carriers. Diagnostic mammography is covered for members with signs or symptoms of breast disease or a history of breast cancer, whether or not they have preventive benefits. AI-based mammography, contrast-enhanced mammography for members who do not meet the medical necessity criteria, and screening mammography in men outside the listed indications are considered experimental, investigational or unproven.
Healthfirst · Identified Oct 2, 2026Medium impact
National Breast Cancer Awareness Month (Oct 2026): Documentation and Coding Resources for Your Practice
Healthfirst has released updated documentation and coding guidance for breast cancer diagnosis and treatment to ensure accurate ICD-10-CM code selection. The policy clarifies how to code malignant neoplasms, metastatic disease, adjuvant therapy (curative vs. prophylactic), and follow-up care, with critical distinctions between active treatment and post-treatment status that directly impact claim coding accuracy.
Aetna · Identified Aug 19, 2026Medium impact
Magnetic Resonance Imaging (MRI) of the Breast (CPB 0105, reviewed 2026-08-06)
Aetna considers breast MRI medically necessary for members who had a recent (within the past year) conventional mammogram and/or breast sonogram, when MRI may affect clinical management. Covered circumstances include detecting local tumor recurrence after mastectomy and breast reconstruction with an implant, assessing residual cancer after an incomplete lumpectomy, and adjunct screening to mammography for women at high genetic risk or with a lifetime breast cancer risk of 20 to 25 percent or more. Breast MRI is considered experimental, investigational or unproven for listed uses such as screening women with average breast cancer risk, evaluating BI-RADS 4 or 5 lesions found on mammogram or ultrasound, and screening women with dense breasts who are asymptomatic and have no additional risk factors. Computer-aided detection is considered integral to breast MRI and is not separately reimbursed.
Aetna · Identified Aug 18, 2026Medium impact
Mammography (CPB 0584, reviewed 2025-09-09)
Aetna considers annual screening mammography medically necessary as a preventive service for women aged 40 and older, and for women under 40 who are judged to be at high risk, such as BRCA1 or BRCA2 mutation carriers and women meeting the other listed risk criteria. Diagnostic mammography is covered for members with signs or symptoms of breast disease or a history of breast cancer, regardless of whether the member has preventive benefits. Digital mammography and digital breast tomosynthesis are acceptable alternatives to film and standard 2D mammography, computer-aided detection is a medically necessary adjunct, and contrast-enhanced mammography is covered only for high-risk members who meet breast MRI criteria but have a documented contraindication, intolerance, or lack of access.
Aetna · Identified Aug 14, 2026Medium impact
Breast Ductal Lavage and Fiberoptic Ductoscopy (CPB 0517, reviewed 2026-08-05)
Aetna considers breast ductal lavage medically necessary as an alternative to aspiration for diagnosing non-lactational sporadic nipple discharge when a direct nipple aspirate yields too little cellular material for adequate cytological analysis. Fiberoptic ductoscopy combined with cytology testing is medically necessary for diagnosing intra-ductal lesions in women with non-lactational sporadic nipple discharge, and as a guide for resection of known breast intra-ductal cancer. Breast ductal lavage for breast cancer screening, breast cancer risk assessment, or any other indication not listed as medically necessary, ductal endoscopy combined with lavage in the contralateral breast of women with ipsilateral breast cancer, fiberoptic ductoscopy with the Acueity System for breast cancer screening, methylation analysis of ductal lavage samples for breast cancer risk, and miRNA analysis of breast ductal fluid for detecting breast cancer are considered experimental, investigational or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Breast and Ovarian Cancer Susceptibility Gene Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy (CPB 0227, reviewed 2026-04-14)
Aetna considers prophylactic mastectomy medically necessary for reduction of breast cancer risk in listed high-risk women, including women diagnosed with breast cancer at 45 years of age or younger, women with a BRCA1 or BRCA2 mutation confirmed by molecular susceptibility testing, and women who received radiation treatment to the chest between ages 10 and 30. Prophylactic bilateral oophorectomy or salpingo-oophorectomy is medically necessary for selected women with listed risk factors who meet specific family history or germline mutation criteria, and germline multigene panel testing is medically necessary once per lifetime for persons who meet one or more NCCN testing criteria for high-penetrance breast cancer susceptibility genes. Testing for BARD1, MUTYH, NBN, and other genes or indications not listed in the policy is not covered.

Watch Z80.3

Get one email when a payer policy names Z80.3, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z80.3?

There are 10 tracked policy changes affecting code Z80.3, including updates from Capital Blue Cross, Blue Cross & Blue Shield of Mississippi, Excellus BlueCross BlueShield. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z80.3?

Payers that have issued tracked updates for code Z80.3 include: Capital Blue Cross, Blue Cross & Blue Shield of Mississippi, Excellus BlueCross BlueShield, Florida Blue, Aetna, Healthfirst.

How do I get notified when code Z80.3 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z80.3. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z80.3?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

AB2026-01-001 Updates and new information

Risk-Reducing Mastectomy

Germline Genetic Testing for Hereditary Cancers 2.02.60

2026 Breast Cancer Screening Coverage Updates

Mammography (CPB 0584, reviewed 2026-09-10)

National Breast Cancer Awareness Month (Oct 2026): Documentation and Coding Resources for Your Practice

Magnetic Resonance Imaging (MRI) of the Breast (CPB 0105, reviewed 2026-08-06)

Mammography (CPB 0584, reviewed 2025-09-09)

Breast Ductal Lavage and Fiberoptic Ductoscopy (CPB 0517, reviewed 2026-08-05)

Breast and Ovarian Cancer Susceptibility Gene Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy (CPB 0227, reviewed 2026-04-14)

What insurance policy changes affect code Z80.3?

Which payers have updated policy for code Z80.3?

How do I get notified when code Z80.3 policy changes?

Why do payers change policies for code Z80.3?